Cabaletta Bio, Inc. (CABA) financial statements and ratios from SEC XBRL: revenue $6.03M (TTM), net margin -2783.2%, revenue growth -39.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $6.03M |
| Net Margin | -2783.2% |
| Revenue Growth (YoY) | -39.8% |
| EPS Growth (YoY) | -10.3% |
| FCF Growth (YoY) | 46.3% |
| Price / Book | 2.52 |
| Price / Sales | 95.38 |
| FCF Yield | -50.1% |
| Altman Z-Score | -3.20 (distress) |
| Sector P/E (Healthcare) | 21.7 |
CABA overview · CABA earnings · CABA KPIs · CABA investor relations · CABA ownership · CABA peers · CABA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.